Biolight AI Stock Analysis
Want to see IL:BOLT full AI Analyst Report?
Biolight (BOLT) AI Stock Analysis
Biolight
(TASE:BOLT)
Biolight's score of 40 (Financials: 50%, Technicals: 30%, Valuation: 20%) reflects a highly speculative, pre-revenue biotech profile. While its robust, debt-free balance sheet provides crucial long-term stability, the stock is heavily penalized by its lack of top-line revenue, continuous cash burn, and deeply negative technical trends.
Biolight (BOLT) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 26.56M
- Dividend Yield
- ―
- Average Volume (3M)
- 11.19K
- Price to Earnings (P/E)
- -2.2
- Beta (1Y)
- 0.64
- Revenue Growth
- -100.00%
- EPS Growth
- -29.02%
- Country
- Israel
- Employees
- 4
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Biolight Business Overview & Revenue Model
Company Description
BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include...
Biolight Financial Statement Overview
Summary
Biolight possesses a strong, virtually debt-free balance sheet with $34.4 million in equity, providing a solid multi-year runway. However, as a clinical-stage biotech, it generates zero revenue and burns roughly $11 million annually, dragging down its overall financial score.
Income Statement
15Very NegativeBalance Sheet
80PositiveCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 219.00K | 118.00K | 63.00K | 3,000 |
| Gross Profit | -270.00K | -544.00K | 219.00K | 118.00K | 63.00K | 3,000 |
| EBITDA | -14.65M | -14.66M | -7.75M | -10.08M | -8.03M | -1.36M |
| Net Income | -11.74M | -11.73M | -7.14M | -26.02M | -7.85M | 382.00K |
Balance Sheet | ||||||
| Total Assets | 35.06M | 42.41M | 34.12M | 33.45M | 57.01M | 64.17M |
| Cash, Cash Equivalents and Short-Term Investments | 16.19M | 23.65M | 13.47M | 8.64M | 17.63M | 33.71M |
| Total Debt | 1.06M | 772.00K | 599.00K | 91.00K | 527.00K | 443.00K |
| Total Liabilities | 3.86M | 2.24M | 3.38M | 3.15M | 3.32M | 2.75M |
| Stockholders Equity | 28.09M | 34.40M | 26.88M | 29.78M | 53.17M | 60.70M |
Cash Flow | ||||||
| Free Cash Flow | -11.92M | -10.86M | -11.02M | -10.99M | -9.64M | -10.65M |
| Operating Cash Flow | -11.92M | -10.85M | -10.99M | -9.58M | -9.54M | -10.03M |
| Investing Cash Flow | -11.96M | -16.17M | 7.55M | -1.95M | -10.55M | 13.48M |
| Financing Cash Flow | 21.36M | 21.37M | 7.98M | 3.25M | -485.00K | 915.00K |
Biolight Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Neutral. The current price of 293.60 is above the 20-day moving average (MA) of 293.38, above the 50-day MA of 290.98, and below the 200-day MA of 317.92, indicating a neutral trend. The MACD of 0.67 indicates Negative momentum. The RSI at 51.51 is Neutral, neither overbought nor oversold. The STOCH value of 92.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:BOLT.
Biolight Peers Comparison
Overall Rating
IL:BLRX41Neutral- IL:BOLT40Underperform
IL:CANF38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IL:BLRX | 41Neutral | ILS 29.87M | -1.00 | ― | ― | -93.07% | 62.25% |
| IL:BOLT | 40Underperform | ILS 26.66M | -2.19 | ― | ― | -100.00% | -29.02% |
| IL:CANF | 38Underperform | ILS 16.23M | -0.23 | ― | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:BOLT | BioLight Life Sciences Ltd. | 293.60 | -95.30 | -24.51% | |
| IL:BONS | Bonus Biogroup | 16.20 | -5.40 | -25.00% | |
| IL:CBI | Clal Biotechnology Industries Ltd | 20.60 | -12.90 | -38.51% | |
| IL:BLRX | BioLineRX Ltd. | 1.00 | -0.70 | -41.18% | |
| IL:CANF | Can-Fite BioPharma Ltd. | 258.90 | 257.90 | 25790.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026